Michael S. Cuffe - Sep 4, 2025 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Role
EVP and Chief Clinical Officer
Signature
/s/ Kevin A. Ball, Attorney-in-Fact
Stock symbol
HCA
Transactions as of
Sep 4, 2025
Transactions value $
-$2,631,903
Form type
4
Date filed
9/8/2025, 06:37 PM
Previous filing
Feb 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cuffe Michael S. EVP and Chief Clinical Officer ONE PARK PLAZA, NASHVILLE /s/ Kevin A. Ball, Attorney-in-Fact 2025-09-08 0001632835

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCA Common Stock Options Exercise $1.89M +10.9K +34.66% $173.12 42.4K Sep 4, 2025 Direct F1, F2
transaction HCA Common Stock Tax liability -$2.92M -7.08K -16.7% $411.59 35.3K Sep 4, 2025 Direct F1, F2
transaction HCA Common Stock Sale -$1.61M -3.84K -10.85% $418.84 31.5K Sep 8, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCA Stock Appreciation Right Options Exercise $0 -10.9K -52.2% $0.00 10K Sep 4, 2025 Common Stock 10.9K $173.12 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025.
F2 Includes 2,595.9017 shares acquired under the Issuer's employee stock purchase plans.
F3 The stock appreciation rights vested in four equal annual installments beginning on February 3, 2022.